ArticleTobacco induced diseases2026
Real-world effectiveness of cytisine, bupropion, and nicotine replacement therapy in a smoking cessation clinic: A single-center retrospective cohort study.
Article in Tobacco induced diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPharmacological treatments such as cytisine, bupropion, and nicotine replacement therapy (NRT) are widely used to support smoking cessation. However, evidence comparing their effectiveness in real-world clinical settings, particularly within smoking cessation outpatient clinics, remains limited.
methodsThis retrospective cohort study evaluated smoking cessation outcomes among patients attending a tertiary smoking cessation outpatient clinic, with follow-up assessments conducted at approximately the first, third, and sixth months. The study was conducted between 1 January 2024 and 28 March 2025. Participants received cytisine, bupropion, or NRT in combination with standardized behavioral counseling. Demographic variables, smoking-related characteristics, treatment adherence, adverse effects, and cessation outcomes were assessed. Smoking cessation was defined as self-reported abstinence during follow-up. Adult patients aged ≥18 years who received smoking cessation treatment were included in the study.
resultsA total of 113 patients were included, of whom 67 (59.3%) successfully quit smoking. Completion of pharmacological treatment was significantly higher among patients who quit smoking compared with those who did not (77.6% vs 30.4%, p<0.001). Cytisine use was more frequent among patients who achieved smoking cessation (58.2% vs 39.1%, p=0.046), whereas bupropion use was higher among those who failed to quit smoking (41.3% vs 20.9%, p=0.019). Nicotine replacement therapy use was not significantly associated with cessation outcomes (p=0.983). Among patients who achieved abstinence, relapse occurred in approximately one-third during follow-up. Improvement in dyspnea was reported more frequently among cytisine users.
conclusionsIn this real-world outpatient setting, cytisine was associated with higher smoking cessation success compared with bupropion and NRT. Treatment adherence emerged as a key determinant of cessation outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.